$MGX SEC Filings

Filed On	Filing
22 Sep 2026	8-K: Regulation FD Disclosure Precision gene editing designed to deliver durable, curative medicines Corporate Presentation September 2026
11 Sep 2026	Form 4: Reid Laurence, Director Bought 20,000 shares ($23.4K)
10 Sep 2026	SCHEDULE 13G
10 Sep 2026	Form 4: Wein Matthew, See Remarks Sold 358 shares ($415)
10 Sep 2026	Form 4: Irish Jian, Director Sold 2,140 shares ($2.48K)
10 Sep 2026	Form 4: Wapnick Pamela, Chief Financial Officer Sold 1,911 shares ($2.21K)
10 Aug 2026	10-Q
10 Aug 2026	8-K: Results of Operations and Financial Condition
11 Jun 2026	Form 4: Reid Laurence, Director Granted 17,400 Stock Option (Right to Buy)
11 Jun 2026	Form 4: Dere Willard H, Director Granted 21,000 Stock Option (Right to Buy)
11 Jun 2026	Form 4: Bjerkholt Eric, Director Granted 21,000 Stock Option (Right to Buy)
11 Jun 2026	Form 4: Eckhardt Juergen, Director Granted 21,000 Stock Option (Right to Buy)
10 Jun 2026	Form 4: Wapnick Pamela, Chief Financial Officer Sold 2,884 shares ($3.75K)
10 Jun 2026	Form 4: Irish Jian, Director Sold 3,737 shares ($4.85K)
10 Jun 2026	Form 4: Wein Matthew, See Remarks Sold 558 shares ($725)
10 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
11 May 2026	10-Q
11 May 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
27 Apr 2026	ARS
27 Apr 2026	Proxy statement: annual meeting on June 9, 2026

Comments